TGen News & Press Releases

Multi-year, 1143-patient genetic study identifies unique types of multiple myeloma

Posted Monday August 19, 2024

TGen-led group confirms high-risk subgroup among cancer patients

TGen researcher seeks FDA meeting on aggregated “n-of-1” clinical trials

Posted Tuesday July 30, 2024

Trials could speed up drug development and personalized medicine

Gene set identifies glioblastomas most vulnerable to promising therapeutic

Posted Tuesday July 9, 2024

Multi-omics study looks at response to neddylation (NAE) inhibitor drugs

TGen Bioscience Leadership Academy Celebrates 2024 Program

Posted Friday June 28, 2024

7th year of foundational biomedical research program encourages careers in science

TGen’s Keri Ramsey Named Recipient of 2024 Claire Chee Award for Excellence in Child Neurology Nursing

Posted Monday June 24, 2024

Award honors an exceptional nurse or nurse practitioner dedicated to caring for children with neurological disorders

Researchers in Phoenix Helping to Chart the Path for the Future of Commercial Space Travel

Posted Thursday June 20, 2024

Their research showed that short-duration space missions do not pose a significant health risk

TGen welcomes next generation of biomedical leaders

Posted Monday June 10, 2024

18th annual Helios Scholars at TGen internship program starts today

Scripps Research, TGen scientists uncover new molecular drivers of Alzheimer’s

Posted Wednesday May 22, 2024

By recording detailed electrical and protein measurements of individual brain cells, researchers revealed new potential drug targets for the neurodegenerative disease

TGen Honors Valley Leader, Nancy Hanley Eriksson, and Exact Sciences Chairman and CEO Kevin Conroy, at its Annual Founders Dinner

Posted Wednesday April 10, 2024

John S. McCain Leadership Award recognizes those whose leadership and dedication advance cancer research and treatment in benefit of patients worldwide

TGen Study Reveals Genetic Drivers of Common Liver Disease

Posted Thursday April 4, 2024

Meta-analysis points to potential new therapeutic pathways

Prev
[1]
2
3
4
5
Next

Media Contact

Galen Perry
[email protected]
602-343-8423

Newsletter

News Archive

View Media Release Archive

OnCline

TGen is a partner with OncLive

2024 © All Rights Reserved TGen. Registered 501(c)(3). EIN: 75-3065445